InterventionsResearch

Paradoxical Renal Protection after Euglycemic DKA in a CKD Stage 4 Diabetic Patient on Empagliflozin: A Case Report and Mechanistic Insights

AHA Scientific Sessions 2025 Abstract

The paper

Uppugandla D, Koppula SR, Gundraju S et al.

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4363027

doi.org/10.1161/circ.152.suppl_3.4363027

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026